Suvorexant, sold under the trade name Belsomra, is a medication for the treatment of insomnia, approved for sale by the U.S. Food and Drug Administration (FDA) in 2014. The U.S. Drug Enforcement Administration (DEA) has scheduled this substance as controlled substance, as it may lead to physical or...